The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, Target, Prudential Financial and Seagate Technology

For immediate publication
Chicago, IL - October 16, 2020 - announces the list of stocks on the Analyst Blog. Every day, analysts at Zacks Equity Research discuss the latest news and events that affect stocks and the financial markets. Stocks recently featured on the blog include: Johnson & Johnson JNJ, Pfizer Inc. PFE, Target Corporation TGT, Prudential Financial, Inc. PRU, and Seagate Technology plc STX.
Here are the highlights from Thursday's analyst blog:
Top analyst reports for J&J, Pfizer and Target
The Zacks Research Daily presents the best research results from our team of analysts. Today's Research Daily features new research on 16 major stocks including Johnson & Johnson, Pfizer and Target. These research reports were selected from the approximately 70 reports our team of analysts published today.
You can find all of today's research reports here >>>
Johnson & Johnson stocks are down -1.0% over the past six months while the Zacks Large Cap Pharmaceuticals industry is up + 1.9%. The Zacks analyst believes the coronavirus pandemic is affecting the company's medical device department due to the decline in elective surgery and the reallocation of hospital resources to treat patients affected by the coronavirus pandemic.
J&J is also facing a number of lawsuits alleging personal injury to patients caused by the use of its drugs, primarily its talc and opioid products. These lawsuits have created uncertainty.
However, the successful market expansion of the blockbuster drugs Imbruvica, Darzalex and Stelara is of great importance. J&J is also making rapid progress with its pipeline and line expansions. (The full research report on Johnson & Johnson can be found here >>>)
Pfizer stock is down -5.9% year-to-date, while the Zacks Large Cap Pharmaceuticals industry is down -0.8%. The Zacks analyst believes the disruption to business from coronavirus, currency headwinds and price pressures are the main headwinds for Pfizer. The company's estimated movement is mixed ahead of the third quarter results. Pfizer has seen mixed earnings surprises over the past few quarters.
The Consumer Healthcare joint venture with Glaxo, the acquisition of Array and the upcoming merger of the Upjohn entity with Mylan will, if successful, make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. Smaller Pfizer should see better sales growth as the Lyrica cliff for loss of exclusivity (LOE) disappears.
(The full research report on Pfizer can be found here >>>)
The target shares have outperformed Zack's retail - discount stores industry in the past year (+ 46.1% versus + 16.8%). The Zacks analyst believes the company has invested resources to improve omni-channel capabilities, develop new brands, renovate stores and expand same-day delivery options to provide a seamless shopping experience. Notably, the company has made multiple changes to its business model to adapt to the ever-evolving retail landscape and stay relevant.
Target's impressive performance in the second quarter of fiscal 2020 is evidence that both profit and profit margins have grown year on year. Notably, like-for-like sales rose for the 13th straight quarter, benefiting from the strength of the digital channel as consumers shifted to online shopping due to coronavirus-induced social distancing.
(You can find the full research report on Target here >>>)
Other notable reports we present today are Prudential Financial and Seagate Technology.
The hottest tech megatrend of all
Last year, the company generated sales of US $ 24 billion worldwide. It is forecast to increase to $ 77.6 billion by 2020. Famed investor Mark Cuban says he will make "the world's first trillionaires," but that should leave plenty of money for regular investors who make the right trades early on.
Check out Zacks' 3 Best Stocks To Play This Trend >>
Media contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. The potential for loss is associated with every investment. This material is provided for informational purposes only and nothing in this document constitutes investment, legal, accounting, tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is made as to whether or not to invest in any suitable for certain investors. There is no assurance that investments have been or will be profitable in any security, company, sector or market that has been identified and described. All information is current at the time of publication and is subject to change without notice. All views or opinions expressed may not reflect those of the entire company. Zacks Investment Research does not engage in investment banking, market making, or asset management activities in any securities. These returns come from hypothetical portfolios made up of stocks with Zacks Rank = 1 that have been rebalanced monthly with no transaction costs. These are not the returns on actual stock portfolios. The S&P 500 is an unmanaged index. Visit for information on the performance metrics shown in this press release.
Click here to get this free report. Johnson Johnson (JNJ): Free Stock Research Report Target Corporation (TGT): Free Stock Research Report Seagate Technology PLC (STX): Free Stock Research Report Pfizer Inc. (PFE): Free Stock Research Report Prudential Financial, Inc. (PRU): Free Stock Research Report To read this article on Zacks To read .com, click here. Zacks Investment Research

Click to receive the most important news as a notification!

Last News

This Is the Real Difference Between Pinot Noir, Cabernet, and Other Red Wines

Man charged in burning of ballot drop box in Boston

Jon Gruden reportedly 'livid' that Bucs-Raiders wasn't rescheduled due to COVID-19

Crews battle fast moving Southern Calif. blaze

US solidifies sanctions against Iran oil before election

Pakistani Navy confirms Brazilian jetliner will replace Orion patrol aircraft